Results 101 to 110 of about 2,367,876 (222)
Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome (MDS)/myeloproliferative disorder most commonly seen in the elderly. We describe an adolescent with monosomy 7 CMML presenting as central diabetes insipidus (DI), who was treated with ...
Boyce, Alison M. +21 more
core +1 more source
Feline hematopoietic neoplasms associated with retroviruses pose a diagnostic and therapeutic challenge, especially when they present with atypical morphological features that do not fit conventional classifications.
Morales Orozco Pablo José +4 more
doaj +1 more source
Genome Aging in Women: Hematopoietic Loss of X Chromosome as An Exemplar
As studies at the intersection of genetics and aging are rapidly advancing, genome aging provides a novel mechanism by which aging phenotypes occur. In this Review, the authors examine the rise, expansion, and the consequences of X chromosome loss in female blood cells.
Xihan Guo, Xueqin Dai
wiley +1 more source
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas +22 more
wiley +1 more source
Summary Unrelated cord blood transplantation (CBT) is an important alternative donor option for adult patients with myelodysplastic syndrome (MDS); however, the prognostic significance of cord blood unit characteristics following CBT remains unclear and may vary according to disease risk.
Takaaki Konuma +23 more
wiley +1 more source
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba +21 more
wiley +1 more source
Secondary chronic myelomonocytic leukemia with t(9;11) in a child
Chronic myelomonocytic leukemia (CMMol) developed in a 10-year-old girl after treatment of non-Hodgkin\u27s lymphoma with a regimen which did not contain epipodophyllotoxins. t(9;11)(p22;q23) was found in the leukemic cells. This case highlights the fact
George R, Pearson ADJ, Evans J, Reid MM
core +5 more sources
Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these ...
Anna Söderström +8 more
wiley +1 more source
The WHO and ICC classifications lack standardized terminology to define the disease phase of chronic myeloproliferative neoplasms in extramedullary sites, particularly lymph nodes, when infiltrates resemble extramedullary hematopoiesis (EH).
Bhaumik Shah +5 more
doaj +1 more source

